Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 12-2021 | |
| Sales | 6 | 156 | 9 | 0 | 0 |
| Cost of Goods | 59 | 106 | 10 | N/A | N/A |
| Gross Profit | -53 | 51 | -1 | N/A | N/A |
| Operating Expenses | 6,169 | 6,653 | 5,741 | 1,734 | 1,300 |
| Operating Income | -6,163 | -6,497 | -5,733 | -1,734 | -1,300 |
| Interest Expense | 58 | 27 | 16 | 15 | 0 |
| Other Income | 17 | -216 | 291 | -1 | 0 |
| Pre-tax Income | -6,204 | -6,739 | -5,458 | -1,750 | -1,300 |
| Income Tax | -137 | N/A | N/A | N/A | 0 |
| Net Income Continuous | -6,067 | -6,739 | -5,458 | -1,750 | -1,259 |
| Minority Interests | -6 | -6 | 0 | -41 | N/A |
| Net Income | $-6,061 | $-6,734 | $-5,458 | $-1,709 | $-1,709 |
| EPS Basic Total Ops | -1.62 | -3.36 | -5.13 | -1.80 | N/A |
| EPS Basic Continuous Ops | -1.63 | -3.36 | -5.13 | -1.83 | N/A |
| EPS Diluted Total Ops | -1.62 | -3.36 | -5.13 | -1.80 | N/A |
| EPS Diluted Continuous Ops | -1.63 | -3.36 | -5.13 | -1.83 | N/A |
| EPS Diluted Before Non-Recurring Items | -1.62 | -3.36 | -5.10 | N/A | N/A |
| EBITDA(a) | $-5,820 | $-6,393 | $-5,733 | $-1,734 | $-1,300 |